Cell-free fetal DNA screening in the USA: A cost analysis of screening strategies

Ultrasound in Obstetrics and Gynecology

Volumn 45, Issue 1, 2015, Pages 74-83

  Evans, M I ^a   Sonek, J D ^b   Hallahan, T W ^c   Krantz, D A ^c  

^a Comprehensive Genetics ^*  (United States)

^b MIAMI VALLEY HOSPITAL   (United States)

^c PERKINELMER INC   (United States)

Author keywords

Aneuploidy serum markers; Cell free fetal DNA; Cost analysis; Down syndrome screening; Nasal bone; Nuchal translucency

Indexed keywords

CHORIONIC GONADOTROPIN BETA SUBUNIT; DNA; PREGNANCY ASSOCIATED PLASMA PROTEIN A;

ADULT; BLOOD; CELL FREE SYSTEM; COST; COST BENEFIT ANALYSIS; ECONOMICS; FEMALE; FETUS ECHOGRAPHY; FIRST TRIMESTER PREGNANCY; GESTATIONAL AGE; HUMAN; MATERNAL AGE; METABOLISM; NUCHAL TRANSLUCENCY MEASUREMENT; PREGNANCY; PRENATAL DIAGNOSIS; TRISOMY; UNITED STATES;

ADULT; CELL-FREE SYSTEM; CHORIONIC GONADOTROPIN, BETA SUBUNIT, HUMAN; COST-BENEFIT ANALYSIS; COSTS AND COST ANALYSIS; DNA; FEMALE; GESTATIONAL AGE; HUMANS; MATERNAL AGE; NUCHAL TRANSLUCENCY MEASUREMENT; PREGNANCY; PREGNANCY TRIMESTER, FIRST; PREGNANCY-ASSOCIATED PLASMA PROTEIN-A; PRENATAL DIAGNOSIS; TRISOMY; ULTRASONOGRAPHY, PRENATAL; UNITED STATES;

EID: 84920868260     PISSN: 09607692     EISSN: 14690705     Source Type: Journal    
DOI: 10.1002/uog.14693     Document Type: Article

References (35)

1. Evans MI, Cuckle HS. Biochemical Screening for Aneuploidy. Expert Reviews in Obstetrics & Gynecology 2007; 2: 765-774.
2. Galen RS, Gambino RA. Beyond Normality: the predictive value and efficiency of medical diagnoses. John Wiley & Sons: New York, NY, 1975.
3. Snijders RJ, Noble P, Sebire N, Souka A, Nicolaides, KH. UK multicentre project on assessment of risk of trisomy 21 by maternal age and fetal nuchal-translucency thickness at 10-14 weeks of gestation. Fetal Medicine Foundation First Trimester Screening Group. Lancet 1998; 352: 343-346.
4. Krantz DA, Hallahan TW, Orlandi F, Buchanan P, Larsen JW Jr, Macri JN. First-trimester Down syndrome screening using dried blood biochemistry and nuchal translucency. Obstet Gynecol 2000; 96: 207-213.
5. Wapner R; Thom E, Simpson JL, Pergament E, Silver R, Filkins K, Platt L, Mahoney M, Johnson A, Hogge WA, Wilson RD, Mohide P, Hershey D, Krantz D, Zachary J, Snijders R, Greene N, Sabbagha R, MacGregor S, Hill L, Gagnon A, Hallahan T, Jackson L, First Trimester Maternal Serum Biochemistry and Fetal Nuchal Translucency Screening (BUN) Study Group. First-trimester screening for trisomies 21 and 18. N Engl J Med. 2003; 349: 1405-1413.
6. Malone, FD, Canick, JA, Ball, RH, Nyberg, DA, Comstock, CH, Bukowski, R, Berkowitz, RL, Gross, SJ, Dugoff, L, Craigo, SD, Timor-Tritsch, IE, Carr, SR, Wolfe, HM, Dukes, K, Bianchi, DW, Rudnicka, AR, Hackshaw, AK, Lambert-Messerlian, G, Wald, NJ, D'Alton, ME, First- and Second-Trimester Evaluation of Risk (FASTER) Research Consortium. First-trimester or second-trimester screening, or both, for Down's syndrome. N Engl J Med 2005; 353: 2001-2011.
7. Lo YM, Corbetta N, Chamberlain PF, Rai V, Sargent IL, Redman CW, Wainscoat JS. Presence of fetal DNA in maternal plasma and serum. Lancet 1997; 350: 485-487.
8. Ehrich M, Deciu C, Zwiefelhofer T, Tynan JA, Cagasan L, Tim R, Lu V, McCullough R, McCarthy E, Nygren AO, Dean J, Tang L, Hutchison D, Lu T, Wang H, Angkachatchai V, Oeth P, Cantor CR, Bombard A, van den Boom D. Noninvasive detection of fetal trisomy 21 by sequencing of DNA in maternal blood: a study in a clinical setting. Am J Obstet Gynecol 2011; 204: 205.e1-11.
9. Palomaki GE, Kloza EM, Lambert-Messerlian GM, Haddow JE, Neveux LM, Ehrich M, van den Boom D, Bombard AT, Deciu C, Grody WW, Nelson SF, Canick JA. DNA sequencing of maternal plasma to detect Down syndrome: an international clinical validation study. Genet Med 2011; 13: 913-920.
10. Bianchi DW, Platt LD, Goldberg JD, Abuhamad AZ, Sehnert AJ, Rava RP, MatErnal BLood IS Source to Accurately diagnose fetal aneuploidy (MELISSA) Study Group. Genome-wide fetal aneuploidy detection by maternal plasma DNA sequencing. Obstet Gynecol 2012; 119: 890-901.
11. American College of Obstetricians and Gynecologists Committee on Genetics. Committee Opinion No. 545: Noninvasive prenatal testing for fetal aneuploidy. Obstet Gynecol 2012; 120: 1532-1534.
12. Bianchi DW, Parker RL, Wentworth J, Madankumar R, Saffer C, Das AF, Craig JA, Chudova DI, Devers PL, Jones KW, Oliver K, Rava RP, Sehnert AJ, CARE Study Group. DNA sequencing versus standard prenatal aneuploidy screening. N Engl J Med 2014; 370: 799-808.
13. Cuckle H, Benn P, Pergament E. Maternal cfDNA screening for Down syndrome - a cost sensitivity analysis. Prenat Diagn 2013; 33: 636-642.
14. Okun N, Teitelbaum M, Huang T, Dewa CS, Hoch JS. The price of performance: a cost and performance analysis of the implementation of cell-free fetal DNA testing for Down syndrome in Ontario, Canada. Prenat Diagn 2014; 34: 350-356.
15. Morris S, Karlsen S, Chung N, Hill M, Chitty LS. Model-based analysis of costs and outcomes of non-nnvasive prenatal testing for Down's syndrome using cell free fetal DNA in the UK National Health Service. PLoS One 2014; 9: e93559.
16. Palomaki GE, Knight GJ, Ashwood ER, Best RG, Haddow JE. Screening for Down syndrome in the United States: results of surveys in 2011 and 2012. Arch Pathol Lab Med 2013; 137: 921-926.
17. Biggio JR, Morris TC, Owen J, Stringer JS. An outcomes analysis of five prenatal screening strategies for trisomy 21 in women younger than 35 years. Am J Obstet Gynecol 2004; 190: 721-729.
18. http://data.bls.gov/pdq/SurveyOutputServlet. Accessed on April 22, 2014.
19. http://www.cms.gov/apps/physician-fee-schedule/. Accessed on April 22, 2014.
20. http://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/ClinicalLabFeeSched/index.html. Accessed on April 22, 2014.
21. Centers for Disease Control and Prevention. National Center for Health Statistics. VitalStats. /nchs/vitalstats.htm. Accessed March 21, 2014.
22. Krantz D, Hallahan T, Ravens R, He K, Cuckle H, Sherwin J, Carmichael J. First trimester Down syndrome screening with dried blood spots using a dual analyte free beta hCG and PAPP-A immunofluorometric assay. Prenat Diagn 2011; 31: 869-874.
23. Cuckle H, Benn P, Wright D. Down syndrome screening in the first and/or second trimester: model predicted performance using meta-analysis parameters. Semin Perinatol 2005; 29: 252-257.
24. Cicero S, Rembouskos G, Vandecruys H, Hogg M, Nicolaides KH. Likelihood ratio for trisomy 21 in fetuses with absent nasal bone at the 11-14-week scan. Ultrasound Obstet Gynecol 2004; 23: 218-223.
25. Cuckle HS, Wald NJ, Thompson SG. Estimating a woman's risk of having a pregnancy associated with Down's syndrome using her age and serum alpha-fetoprotein level. Br J Obstet Gynaecol 1987; 94: 387-402.
26. Spencer K. What is the true fetal loss rate in pregnancies affected by trisomy 21 and how does this influencewhether first trimester detection rates are superior to those in the second trimester? Prenat Diagn 2001; 21: 788-789.
27. Odibo AO, Stamilio DM, Nelson DB, Sehdev HM, Macones GA. A Cost-effectiveness analysis of prenatal screening strategies for Down syndrome. Obstet Gynecol 2005; 106: 562-568.
28. Garfield SS, Armstrong SO. Clinical and cost consequences of incorporating a novel non-invasive prenatal test into the diagnostic pathway of fetal trisomies. J Managed Care Med 2012; 15: 34-41.
29. Bredaki FE, Poon LC, Birdir C, Escalante D, Nicolaides KH. First-trimester screening for neural tube defects using alpha-fetoprotein. Fetal Diagn Ther 2012; 31: 109-114.
30. Nicolaides KH, Wright D, Poon LC, Syngelaki A, Gil MM. First-trimester contingent screening for trisomy 21 by biomarkers and maternal blood cell-free DNA testing. Ultrasound Obstet Gynecol 2013; 42: 41-50.
31. Spencer K, Nicolaides KH. A first trimester trisomy 13/trisomy 18 risk algorithm combining fetal nuchal translucency thickness, maternal serum free beta-hCG and PAPP-A. Prenat Diagn 2002; 22: 877-879.
32. Souka AP, von Kaisenberg CS, Hyett JA, Sonek JD, Nicolaides KH. Increased nuchal translucency with normal karyotype. Am J Obstet Gynecol 2005; 192: 1005-1021.
33. Sonek JD, Cuckle HS. What will be the role of first-trimester ultrasound if cell-free DNA screening for aneuploidy becomes routine? Ultrasound Obstet Gynecol 2014; 44: 621-630.
34. Dugoff L, Hobbins JC, Malone FD, Porter TF, Luthy D, Comstock CH, Hankins G, Berkowitz RL, Merkatz I, Craigo SD, Timor-Tritsch IE, Carr SR, Wolfe HM, Vidaver J, D'Alton ME. First-trimester maternal serum PAPP-A and free-beta subunit human chorionic gonadotropin concentrations and nuchal translucency are associated with obstetric complications: a population-based screening study (the FASTER Trial). Am J Obstet Gynecol 2004; 191: 1446-1451.
35. Krantz D, Goetzl L, Simpson JL, Thom E, Zachary J, Hallahan TW, Silver R, Pergament E, Platt LD, Filkins K, Johnson A, Mahoney M, Hogge WA, Wilson RD, Mohide P, Hershey D, Wapner R. Association of extreme first-trimester free human chorionic gonadotropin-beta, pregnancy-associated plasma protein A, and nuchal translucency with intrauterine growth restriction and other adverse pregnancy outcomes. Am J Obstet Gynecol 2004; 191: 1452-1458.